If you have first-hand experience of Autism in your life, or like most, have lost close loved ones to a horrible painful death due to Cancer, it is likely that it was all so unnecessary . . and evidence points to this health-hijacking component inserted into our society is also a huge factor in Heart Disease as well . . and this will continue IF there is not some sort of outrage . . which it seems to me that most people just accept these things as inevitable, and that there is no way that information like what is in this post could really be true . . after all, it would be all over the TV and radio, right? . . the same people and $$ that ultimately profits from illness and death also owns the media . . never forget that
Autism
85% respond and 15% have their autism eradicated.
- Patient Resources
- Autism
- Report from Italian families treating children with GcMAF
- What improvements did parents report?
Dr
Jeffrey Bradstreet has now treated over 2,000 autistic children with
GcMAF and the results are well established. In 15% GcMAF makes no
difference. 85% improve, if only a little, and of them 15% have their
autism eradicated. In all 3,000 children have been treated with GcMAF
with similar results.
And Dr Bradstreet has published a paper: “Initial Observations of Elevated Alpha-N-Acetylgalactosaminidase Activity Associated with Autism and Observed Reductions from GC Protein—Macrophage Activating Factor Injections“ which is ground breaking in its discoveries.
With Dr Bradstreet we ourselves published a groundbreaking paper in “Frontiers in Neurology” on the 2nd January 2014 where we identify, for the first time, the point in the human brain where autism resides.
In our opinion Autism tends to be caused by the MMR and other vaccines putting viruses and mercury into children. A shortage of lipids may contribute. Another Italian court has awarded €178,000 against the government to a family who’s child contracted autism from MMR.
These viruses sabotage the immune system by sending out nagalase to prevent the production of the child’s GcMAF, and therefore become chronic.
Autism is usually a viral disease to a greater or lesser extent, with viruses in the brain and the stomach. In 15% of children viruses are negligible, and GcMAF probably will not help. In 85% viruses are involved, and they will respond to GcMAF. In 15% of children autism is mainly a viral disease, and these children make full recoveries.
Children can begin to respond inside 5 weeks. If nothing happens in 16 weeks, their autism may not be viral. If they respond, GcMAF should be continued for typically 24 weeks, or 8 weeks after they appear to be recovered, to ensure the viruses does not return.
GcMAF has three excellent effects in the brain and rebuilds the immune system, which then attacks the viruses that cause autism. Improvements in the child are often seen as early as five weeks – about the same time it often takes to permanently eradicate the herpes virus. We recommend a child starts at 0.03ml, with a second 0.03 dose in three days, to build up to a twice weekly 0.1ml dose as soon as possible. Make sure he eats plenty of lipids. But see Dr Antonucci’s recommendations below.
Children with autism often have very high levels of vitamin D3, occasionally toxic levels (and low levels of D2) which may be produced by gut bacteria. We do not recommend any change to vitamin D3 (which may result in severe hyperactivity) or any change to anything else, until you are four weeks in with the GcMAF. Even then, not unless the child has had a vitamin D level test. So change nothing else at the time you start GcMAF, or preferably Goleic.
------------------------------------------------------------------------------------------------------------------------
http://www.faim.org/autism/gcmaf-treatment-cancer-autism-inflammation-viral-bacterial-disease.html
GcMAF for the treatment of cancer, autism, inflammation, viral and bacterial disease
by David Noakes
David Noakes
Human GcMAF, otherwise known as Vitamin D binding protein macrophage activating factor, holds great promise in the treatment of various illnesses including cancer, autism, chronic fatigue and possibly Parkinson's. Since 1990, 59 research papers have been published on GcMAF, 20 of these pertaining to the treatment of cancer. 46 of these papers can be accessed through the GcMAF web site.
GcMAF is a vital part of our immune system which does not work without it; and is part of our blood. GcMAF stimulates the macrophage element of the immune system to destroy cancer cells. It also blocks the supply of nutrients to cancer cells by stopping blood vessel development to the site (anti-angiogenesis). Cancer cells are weakened and starved, making them more vulnerable to attack by the GcMAF stimulated macrophage system. Research has shown macrophage activation and stopping diseased blood vessel development can also help in various neurological diseases such as Parkinson's, Alzheimer's, rheumatoid arthritis, inflammatory conditions, and diabetic retinopathy.
David Noakes
In the case of autism, Dr. James Bradstreet has so far treated 1,100 patients with GcMAF with an 85% response rate. His results show a bell curve response with 15% of the patients showing total eradication of symptoms and 15% showing no response.
In addition, experimental and clinical evidence confirms that GcMAF shows multiple powerful anti-cancer effects that have significant therapeutical impact on most tumors including breast, prostate, and kidney. GcMAF is created in the body by the release of two sugar molecules from a GcProtein molecule.
However, tumors release an enzyme known as Nagalase. Nagalase degrades GcProtein to the point it is unable to become GcMAF. Since GcMAF only lives for about a week in the body, without continuous conversion of GcProtein the stores of GcMAF are depleted rapidly in the presence of Nagalase. However, Nagalase can only destroy GcProtein and not GcMAF. Thus the introduction of external GcMAF through injection into the body has been shown to be effective.
GcMAF has no side effects of its own, but in under 10% of cases the immune system, which will be rebuilt in just three weeks, can produce considerable side effects in autistic children. The treatment consists of an injection with a tiny diabetic sized syringe once a week. The duration depends on the severity of the disease. Research also reveals that in cancer cases that are stage I and II, the success rate approaches 90% inside 6 months. Nagalase and immune system levels can be measured in the blood and thus offer a marker for cancer and other diseases.
In conclusion, GcMAF restores the energetic balance in the cell. Cancer cells driven by sugar metabolism become healthy oxygen driven cells, so tumor cells no longer behave as parasitic organisms. GcMAF stimulates macrophages to consume the cancer cells and cells invaded by viruses. This stimulation of the immune system and the anti-angiogenetic effect surrounding the tumor is beneficial in cancer and several neurological disorders like autism, chronic fatigue, Parkinson's, and Alzheimer's, and it is available to the general public.
The following testimonials are from the gcmaf.eu web site:
Autism
Hello Dr. Bradstreet, After 13 weeks of the GCMAF, we are happy to report that she continues to have tremendous gains in all areas. Increased socialization and speech, better performance in the school as well as community settings, decreased tantrums and less vocal protests, she is able to change activities and transition to non preferred tasks. It has been absolutely amazing, all her therapists, teachers, other parents have remarked about her good behavior in public places (for example, grocery stores, department stores such as Nordstrom's, Macy's, The Zoo, Bowling, the library, parks and playgrounds. In the past, we never went to these places in fear of her stimming, or her behavior (45 minute tantrums). Now, she surprises us as well as others with her appropriate comments and follows direction very well. Before she would only eat one thing (french fries) and now she eats everything including vegetables!!!!! I've sent some pictures to show her progress. We are so excited to see what more phenomenal things are in the future to come!
Ovarian and lung cancer
I first contracted cancer in the form of a granulosa cell tumour in 2005. After 2 operations and 3 months of chemo by January 2010 it had reached stage 4 and had spread from my ovaries to my lungs. After that scan in January I was told the chemo had failed, my 5 tumours were still growing, given Tamoxifen hormone, told I had between 3 months and 2 years left to live, and sent on my way.
I started taking GcMAF at the age of 56 on 16th May 2010; the only feeling or side effect I have from GcMAF is I felt almost from the beginning that I had my old energy back and was feeling much better and fitter in myself. After 8 weeks of taking only GcMAF and Tamoxifen I went for a scan. This showed all tumours had shrunk, the four in my lungs were now hardly noticeable and that the aggressive tumour in my pelvis had shrunk from 7.4cm to 4.1 cm. This is a significant decrease in size.
The stand-in consultant was very excited, and said these were excellent results. As I did not know her, and she did not ask, I did not tell her why.
On the 21st Oct I had another scan; the improvements continued; the secondaries appeared to be merely scar tissue, and the pelvic tumour had shrunk to 3.5 cm
In the winter my improvements seemed much slower; we now know because GcMAF needs normal vitamin D levels. But I've just got back from a wild month in Australia and Thailand, the sunshine should have done wonders for my vitamin D levels, and for my next scan. I will keep you updated. But I am over the moon and feel better than ever. And yes, you can phone me if you like. Gail in London.
Breast cancer
"I have the opportunity to treat patients from all over the World and the addition of GcMAF for my cancer patients is truly adding a new dimension not previously available to us. Recently I have been following a 42 year old women who had already undergone surgery, radiation and chemotherapy for stage IIIB breast cancer. I obtained a nagalase test through ELN (Holland) and it returned in the very elevated range of 4.20nmol/min/mg (normal reported by this lab does not exceed 0.95). Her other tumor markers were not elevated, but her PET scan demonstrated a likely metastatic site in the hip bone.
After discussing her options the patient wanted to try GcMAF therapy prior to considering more radiation or chemotherapy. After 6 weeks of GcMAF 100ng/week subcutaneous injections (much like a shot of insulin) her repeat nagalase test returned at 2.10 (a 50% reduction). All of her other tumor markers remain negative and she is taking the dose of Vitamin D3 required to optimize her blood levels (9000 iu/day). It is too soon for her PET to be repeated but we will follow this soon to determine the course of the bone metastasis. The nagalase test may be a more sensitive marker for tumor burden than other more accepted blood tests. GcMAF given via simple patient administered once weekly injections is clearly able to reduce the nagalase level dramatically over a short period of time. In previous published studies, nagalase response to GcMAF was correlated with reduction and eventual elimination of cancer. This is an encouragement to us all and I will keep you posted on the patient's progress."
For more information please visit First Immune GcMAF or contact David Noakes at:
First Immune GcMAF
Clos de Balade 21
1140 Evere
Brussels, Belgium
Phone +44-7781-411-737
Clos de Balade 21
1140 Evere
Brussels, Belgium
Phone +44-7781-411-737
-------------------------------------------------------------------------------------------------------------------------
AGE OF AUTISM
Dr. Bradstreet, Nagalase, and the Viral Issue in Autism
Although my daughter is not a patient of Dr. Jeff Bradstreet I've always had an enormous amount of respect for the good doctor. I'll usually go on his website once or twice a month to find out what has most recently attracted his interest. Often it seems we're looking at similar questions; which either means great minds think alike, or we suffer from some of the same delusions.
I was intrigued by his October 11, 2011 entry, "An Update on Viral Issue in Autism" since it dovetailed with some of my own recent investigations.
In the past months Dr. Bradstreet has become interested in nagalese, which he describes as an enzyme "produced by cancer cells and viruses." He thinks it unlikely that children with autism have undiagnosed cancers, and thus suspicion falls on a viral etiology. Dr. Bradstreet writes, "Viruses make the nagalese enzyme as part of their attachment proteins. It serves to get the virus into the cell and also decreases the body's immune reaction to the virus-thereby increasing the odds of viral survival."
Further on Dr. Bradstreet writes, "It is reasonable and likely that the nature of the immune dysfunction and the frequently observed autoimmune problems in autism are mediated by persistent, unresolved viral infections." He claims to have tested approximately 400 children with autism for the viral marker, nagalese, and found that nearly 80% have significantly elevated levels. He hopes to publish soon on this study and believes this information "is one of the most important developments in the clinical treatment of children on the spectrum that I have experienced in the last 15 years."
Dr. Bradstreet's article got my attention because of my daughter's own nagalese testing. I had her tested back in May (when she'd endured three hospitalizations due to uncontrolled seizures) and her reading was 3.3 (reference range 0.35-0.95). In desparation we tried the ketogenic diet (high fats and low carbs), and although there have been some rough patches since May we have avoided further hospitalizations.
And her stools normalized.
Yes, I know all of you realize how important that is. We're talking months and months of good stools. Seizures down at least 80%. So of course, your friendly neighborhood science teacher was interested in what her nagalese levels might be, so we did a retest in late September. This time her reading was 1.7. It was about a 50% drop, and while it's still abnormal, it is progress. It makes me wonder if a low-carb diet starves viruses of an energy source.
There are critics of nagalese testing. Dr. Enlander, a specialist in chronic fatigue syndrome/ME, another disease which may be viral in origin, doesn't believe the tests are sensitive enough to be of any value. And he may be right.
Dr. Bradstreet also discusses a substance called GcMAF, which I don't have enough information about to make an informed judgment, and that after viral clearance, the possibility of using neuronal stem cells which can cross the blood-brain barrier. I really can't comment on the advisability of either suggestion.
But if you are like me, still looking for that clue which might help your child join the ranks of the recovered, you might investigate nagalese.
Kent Heceknlively is a Contributing Editor to Age of Autism
The GcMAF Book
Nagalase: Friend and Foe?
What is Nagalase?
Nagalase is a protein made by all cancer cells and viruses (HIV, hepatitis B, hepatitis C, influenza, herpes, Epstein-Barr virus, and others). Its formal, official chemical name is alpha-N-acetylgalactosaminidase, but this is such a tongue-twisting mouthful of a moniker that we usually just call it “Nagalase.” (Sometimes, when I want to impress friends with my brilliance, I’ll say the entire word real fast: “alpha-N-acetylgalactosaminidase.” I have found that it’s important to practice beforehand if one doesn’t want to embarrass oneself.)
Why is Nagalase important?
- Nagalase causes immunodeficiency. Nagalase blocks production of GcMAF, thus preventing the immune system from doing its job. Without an active immune system, cancer and viral infections can grow unchecked.
- As an extremely sensitive marker for all cancers, Nagalase provides a powerful system for early detection.
- Serial Nagalase testing provides a reliable and accurate method for tracking the results of any therapeutic regimen for cancer, AIDS, or other chronic viral infection.
Nagalase proves that cancer cells break all the rules
Normal healthy cells cooperate with one another in a concerted effort to further the good of all. Cancer cells refuse to play ball. Their disdainful attitude toward the rest of our cellular community is appalling. For example, these cellular scofflaws ignore clear messages to stop growing and spreading and encroaching on their neighbor’s space. How would you like it if your neighbor moved his fence over into your backyard?
Of all the rules cancer cells break, none is more alarming than the production of Nagalase, the evil enzyme that completely hog-ties the immune system army’s ability to stop cancer cells.
Virus particles also make Nagalase. Their goal is the same as that of the cancer cells: survival by incapacitating their number one enemy: the immune system.
Nagalase precision
Like a stealth bomber, the Nagalase enzyme synthesized in and released from a cancer cell or a virus particle pinpoints the GcMAF production facilities on the surface of your T and B lymphocytes and then wipes them out with an incredibly precise bomb. How precise? Let me put it this way: Nagalase locates and attacks one specific two-electron bond located at, and only at, the 420th amino acid position on a huge protein molecule (DBP), one of tens of thousands of proteins, each containing millions of electrons. This is like selectively taking out a park bench in a major city from six thousand miles away. More astonishing, if that is possible, Nagalase never misses its target. There is no collateral damage.
As you already know, GcMAF is a cell-signaling glycoprotein that talks to macrophages, enabling them to rapidly find, attack, and kill viruses and cancer cells. By activating macrophages, GcMAF triggers a cascade that activates the entire immune system. Blockage of GcMAF production by Nagalase brings all this wonderful anti-cancer and anti-viral immune activity to a screeching halt, allowing cancer and infections to spread.
What does Nagalase actually do? How does it destroy immune functioning and deactivate macrophages?
Once synthesized and released into nearby tissue or into the bloodstream, Nagalase, like that drill sergeant at boot camp, shouts harsh commands at the vitamin D binding protein (DBP) that is about to be turned into GcMAF. Nagalase demands that DBP not, under any circumstances, attach itself to a specific sugar molecule (galactosamine). If DBP has already grabbed (i.e., connected to, using a two-electron, “covalent” bond) a galactosamine sugar molecule, it is commanded to immediately let go. “Leave galactosamine alone, or you’ll be in big trouble!!!” is the Nagalase sergeant’s command. We’ll probably never know whether or not, on some deeper level, DBP knows that Nagalase’s motives are dastardly—but it doesn’t really matter: DBP will definitely always obey. Like the army private, the DBP literally has no choice. Because of the way hierarchies work in cellular biology, proteins must do the bidding of their enzymes. The enzymes, like Nagalase, are the drill sergeant and the proteins, like DBP, are the privates. That’s just the way it is. Obeying the drill sergeant’s command means DBP can’t do its assigned task, that of becoming GcMAF. It is rendered useless. For DBP, on a molecular level, life no longer has meaning.
Unfortunately for cancer and viral patients, DBP had been on its way to becoming GcMAF until the Nagalase drill sergeant so rudely interrupted. Now GcMAF—the one protein our bodies need in order to activate our immune systems—can’t be made. Immune activity screeches to a halt. The defense system protecting us from cancers and viruses has been snuffed out.
Nagalase, using this astonishingly simple yet cunningly subversive technique, emasculates the GcMAF precursor protein (DBP) by knocking off its three sugar molecules. One quick whack by Nagalase and the DBP protein that would have become a GcMAF molecule now limps off into the sunset, permanently disfigured and disabled. With one simple, swift maneuver, Nagalase has brought the entire immune system to its knees.
Here’s how Dr. Yamamoto put it (for clarity, I’ve replaced some of the technical words):
“Serum vitamin D3-binding protein (DBP) is the precursor for the principal macrophage activating factor (GcMAF). The precursor activity of serum DBP was reduced… These patient sera contained alpha-N-acetylgalactosaminidase (Nagalase) that deglycosylates (removes the sugars from) DBP. Deglycosylated DBP cannot be converted to GcMAF, thus it loses the GcMAF precursor activity, leading to immunosuppression.” (Microbes Infect. 2005 Apr;7(4):674-81. Epub 2005 Mar 22. Pathogenic significance of alpha-N-acetylgalactosaminidase activity found in the hemagglutinin of influenza virus. Yamamoto N, Urade M.)
Nagalase testing: former mass murderer now works for the good guys
It’s easy to be a little schizy about Nagalase. On the one hand, this nasty protein’s behavior toward us has been reprehensible and disastrous. Working in cahoots with cancer and HIV—not shy about getting into bed with our mortal enemies—Nagalase can rightfully claim direct responsibility for billions of human deaths. And it would just as soon add you to the list, so we don’t have to be shy about placing Nagalase in the “genocidal murderer” column.
With the advent of Nagalase testing, however, this bad actor now will be harnessed to a useful purpose. By providing us with precise and reliable advance information about enemy operations, Nagalase blood level testing becomes a “Deep Throat” double agent for cancer. He helps us by giving us an early warning sign.
Early detection (using AMAS or Nagalase) saves lives
You don’t want a cancer to have gotten out of control by the time you find and start treating it. When cancers are still young and small, gentle natural therapies are the most effective. Alternative treatments work best on early small cancers by enhancing immune functioning and removing the source of the inflammation that is causing the cancer in the first place. Cancers that have become large enough to see on imaging pose a much more significant threat, and the big guns now become necessary.
The current method for diagnosing most cancers requires us to wait until a mass shows up on imaging (e.g., a mammogram, chest X-ray, or colonoscopy). This approach wastes valuable time and causes needless deaths. But long before imaging can find it, a positive Nagalase (or AMAS test) can tell us that early stage cancer exists somewhere in the body. By enabling earlier and therefore less invasive treatment options, this information provides a huge head-start.
Normally present at only trace levels, Nagalase shows up in the blood when a cancer or virus appears
The malignant and viral entities that make Nagalase are not normally present, so its appearance is a big deal from a diagnostic perspective. When Nagalase shows up, even in very small amounts, we have the earliest glimpse of a new cancer or viral infection. The old adage, “Where there’s smoke, there’s fire” applies here. A positive Nagalase test notifies us that a cancer (or a nasty virus) lurks within.
Nagalase appears in the blood stream when a nascent cancer is just a minute cluster of abnormal cells, long before conventional diagnostic methods can detect it. Through blood testing, we can find this red flag, even when present at exceedingly low levels. Providing us with this early warning sign might not quite qualify Nagalase for the “Good Samaritan” award, but I could go with “extremely useful.” Like a rehabilitated criminal on parole, the potential for harm is still there. For now, however, he’s staying out of trouble and doing community service. Turn your back and he’s a mass murderer again.
Using Nagalase testing to track cancer treatment
Rising Nagalase levels indicate a cancer or virus is growing and spreading. Conversely, Nagalase levels will decrease if the cancer or infection is being effectively destroyed.
Any treatment that lowers cancer cell (or viral numbers) will lower Nagalase levels. Nagalase will, for example, always drop after surgery (whether or not the entire tumor was removed). Chemotherapy and radiation also reduce Nagalase levels. So does GcMAF. If, after these treatments, the depressed level begins to rise again, this is the warning sign that the cancer was not completely removed, and/or that metastatic disease is hiding out somewhere. With viral infections, increasing Nagalase levels indicate return of the infection.
Consecutive rising Nagalase levels are therefore a red flag, warning us it may be time to entertain new treatment options. Conversely, if levels are going down, stay the course: the cancer or virus is going away.
Flat-earth medicine
Many medical professionals don’t feel comfortable with “nonspecific” tests like Nagalase. It drives them nuts to discover that a cancer is lurking somewhere inside without knowing exactly where it is located. “How,” they ask, “do you expect me to treat a cancer I can’t see? Why, I’m not going to tilt at windmills!” This may be a signal that you need to find a different doctor, perhaps one who works in an alternative cancer clinic. Here you will find highly-trained professionals who understand the concept that cancer is a molecular biological change long before it presents visually (by this I mean becomes viewable on imaging).
When GcMAF becomes available, the answer will be easier: a six month course of weekly 100 ng GcMAF intramuscular injections with monthly Nagalase level tests to follow the Nagalase level as it goes back down to baseline. The cancer can be declared cured, even though it never reached life-threatening proportions. (We have a long way to go before this kind of medical behavior will be commonplace and acceptable. The sooner the better, however.)
Nagalase role “under-appreciated”
Nagalase, arguably our most immunosuppressive protein molecule, poses an enormous threat in terms of cancer perpetuation and viruses’ ability to continually defeat us. Yet cancer researchers have not shown any interest in it. (Maybe I’m being a little too generous here; perhaps “clueless” would be more a more accurate depiction.) Why don’t they get it that blasting cancer cells into oblivion with chemo and radiation is usually not sufficient to stop advanced disease and does nothing to address the cause: immunosuppression. Even if we ignore for the moment the excessive collateral damage caused by chemo drugs and radiation, the patient also needs—requires—a healthy immune system to finish the job. If we don’t revive immune function by disabling Nagalase, the cancers and viruses will just keep roaring back. Restoring immunocompetence by negating the stultifying effect of Nagalase should therefore become a primary research goal.
--------------------------------------------------------------------------------------------------------------------------------
Update July 16 2015: GcMAF is no longer available as the company that made it was shutdown by overseas regulatory agencies. As always, consult your doctor before making any medical decisions on any therapy you may be considering.
Update July 25, 2015: My use of GcMAF for my own personal health recovery, which was guided by a doctor, started in 2011 and ended in 2013. The information on this page has not been updated in some time other than the comment above. Some have contacted me recently asking for more information on GcMAF. Unfortunately, I do not have any further details and suggest that people discuss any potential medical treatment option with their doctor. I am not a doctor and am simply sharing my personal experience having explored this option a few years ago.
GcMAF (Gc protein macrophage activation factor) is an immune-regulating compound from Europe that may have benefit for those of us struggling with immune system health. It has been used in HIV and cancer for several years. More recently, doctors and researchers have been considering GcMAF for use in patients with illnesses that most of us will recognize.
From gcmaf.eu, "In its role of immune system regulator, research shows GcMAF can reverse other diseases that attack the immune system like Autism, CFS, XMRV, Lyme disease, Aids, HIV, Fibromyalgia (all of which we've begun to have success with ourselves), osteoporosis, Hodgkin’s, Lupus, MS, Parkinson’s, various bacterial and viral infections and various types of Immune dysfunction."
I first heard about GcMAF almost a year ago. At the same time, I had first learned about "nagalase", a blood test that is used to in part determine whether or not one might be a candidate for GcMAF therapy. Nagalase is an enzyme that prevents Vitamin D receptors (VDR) from being activated on the surface of the macrophage. As a result, macrophages are not "activated" and our immune systems are not able to properly respond to invaders.
Here are some points that I have learned thus far on GcMAF:
- GcMAF has reportedly been tested more for safety, purity, etc. than other human blood products.
- Macrophages are cultured, destroyed, and the GcMAF receptors are purified.
- Treatment is via injection 1x/week for 8-20 weeks. Dose is titrated initially to avoid exacerbation or Herx responses as much as possible.
- A commonly used dose is .25ml once weekly (a 2.2 ml vial should last 8 injections).
- The primary test used in looking at whether or not GcMAF may be a reasonable intervention is nagalase.
- Nagalase inactivates macrophages.
- I personally would NEVER consider this option without having a baseline nagalase test. Normal is < 0.95. Mine was 2.9.
- The practitioner I worked with suggested that 2.9 was in the range of someone with HIV or cancer in terms of the impact on the immune system. I'd like to hear from others in the Lyme community as you get test results as well to see if there is a pattern of elevated nagalase in those with Lyme disease. Whether or not Lyme itself has anything to do with nagalase elevation is something I have not been able to find anything on. We certainly all have underlying viral co-factors that are likely in play as well, but I suspect that Borrelia may also play a role in nagalase elevation.
- In healthy college students, a nagalase 0.4 is not uncommon (the lower the better).
- At 2.9, my practitioner was surprised that I did not have more cognitive deficits such as memory loss and other cognitive issues.
- It has been suggested that ongoing antimicrobial therapy without a working immune system is like leaving the house with the door wide open inviting burglars in. By using GcMAF to activate macrophages, nagalase drops, and one may regain a functional immune system. The door is then closed to further invaders and we may no longer serve as a microbe hotel.
- Maintenance therapy should not be needed once the immune system is once again properly functioning.
- Activated macrophages only remain active for 7 days so any negative responses are generally short-lived. That said, some people do have strong inflammatory responses that are not believed to be typical die-off reactions.
- It has been indicated that in some cases, other medications may be needed in order to manage the inflammatory response. This is another reason that one needs to be working closely with a knowledgeable practitioner before considering GcMAF in my opinion. In the CFS and GcMAF world, this more severe form of a die-off reaction is called IRIS.
- VDR genetics do not seem to play a role in predicting response as earlier thought according to one practitioner that I have spoken with. That said, Vitamin D levels do correlate with the positive response rate of GcMAF. Thus, Vitamin D supplementation may be required in order to optimize outcome.
- Other than die-off reactions or activation of symptoms (inflammation), no other side effects are generally expected.
- Nagalase should be monitored every 1-2 months while on treatment to determine the required duration of the therapy. Target nagalase after treatment would be 0.4 to 0.6.
- Elevated nagalase has a profound detrimental effect on the immune system. Elevated nagalase is often presumed to be related to microbes of viral origin or cancer. Viruses that are nagalase producers open the door to chronic infections.
- Hemagglutinin contains nagalase and is also found in flagella of some bacteria so it could also be the case that some bacteria may produce nagalase.
- Parents with ASD children also often have elevated nagalase.
- A practitioner I spoke with likened Lyme disease to a "peat moss fire" burning below the surface. Activating macrophages should help to deal with the fire.
- GcMAF should be helpful in dealing with other infections that are not of viral origin; for example, Borrelia, Bartonella, and other infections commonly associated with Tick-Borne Infections (TBIs). GcMAF is active against many cancers and many different kinds of microbes.
- Neopterin is another test that is sometimes used as an indicator of immune suppression. As macrophages become activated, neopterin may rise and later fall. If one is in the normal range for neopterin and has an immune-related illness, this could be an indication that the immune system is suppressed and not responding appropriately.
- People with autoimmune conditions can generally use GcMAF. However, GcMAF may be contraindicated in people with Multiple Sclerosis.
- Reduction in nagalase is generally seen early in the course of treatment; within the first 3-6 weeks. In some studies, nagalase dropped by over 50% in less than six weeks.
- Cancer patients may initially feel as bad on GcMAF as they do on chemotherapy, but often feel much better after the first month.
- Anti-inflammatories may limited the effect of GcMAF.
- Enzymes and biofilm-reducing supplements may have a negative impact on GcMAF therapy and may be best avoided. It is still too early to know what the impact may be, but one practitioner I spoke with feels that it is best to avoid these.
- One should not be on any immune-suppressing agents while on GcMAF as the immune system must be partially functional in order to respond appropriately to the treatment.
- A common pattern is to see elevated lymphocytes, high nagalase, and low NK cells. Once nagalase drops, it may be the case that NK cell function could be positively impacted. CD57 is a type of NK cell. It is too early to know if this proves to be true, but it is one of the things I'm quite interested in.
Continue HERE
The Gonzalez Protocol: A Natural Approach to Healing
It is with great sadness that the office of Nicholas J. Gonzalez, M.D. relays news of his untimely death on Tuesday, July 21, 2015. The cause of death was cardiac related, it appears, as he suddenly collapsed and was unable to be revived. Dr. Gonzalez was in excellent health otherwise so his passing is quite unexpected.
Currently, his family is taking care of final arrangements and Dr. Linda Isaacs and his office staff are tending to patients. For updates, please subscribe to the office announcement list in the left hand menu. Moving forward, his team will do their best to navigate tasks and transitions seamlessly and we thank you in advance for your kind consideration.
Dr. Gonzalez leaves a legacy of faith, healing, and genuine love for people and the pursuit of medicine. We are heartbroken at this loss, but determined to keep his work and his memory alive.
- Dr. Nicholas Gonzalez provides individualized nutritional regimens for many types of cancer, as well as other illnesses such as Lyme, allergies, autoimmune disorders and chronic fatigue
- Over 30 years of research and clinical experience
- Private practice in New York City since 1987 with his colleague Dr. Linda Isaacs
No comments:
Post a Comment